SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:2ae4db3b-b59d-4e03-becb-43214eb0229d"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:2ae4db3b-b59d-4e03-becb-43214eb0229d" > Safety, immunogenic...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005812naa a2200673 4500
001oai:lup.lub.lu.se:2ae4db3b-b59d-4e03-becb-43214eb0229d
003SwePub
008180504s2018 | |||||||||||000 ||eng|
009oai:DiVA.org:uu-366863
0247 a https://lup.lub.lu.se/record/2ae4db3b-b59d-4e03-becb-43214eb0229d2 URI
0247 a https://doi.org/10.1111/ajt.147332 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3668632 URI
040 a (SwePub)lud (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Lorant, Tomas,d 1975-u Uppsala universitet,Uppsala University,Transplantationskirurgi4 aut0 (Swepub:uu)tomalora
2451 0a Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
264 1b Elsevier BV,c 2018
520 a Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG-degrading enzyme of Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single-center, open-label ascending-dose study in highly sensitized patients with chronic kidney disease. Eight patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2 intravenous infusions of IdeS on consecutive days (0.12 mg/kg body weight ×2 [n = 3]; 0.25 mg/kg ×1 [n = 3], or 0.25 mg/kg ×2 [n = 2]). IgG degradation was observed in all subjects after IdeS treatment, with <1% plasma IgG remaining within 48 hours and remaining low up to 7 days. Mean fluorescence intensity values of HLA class I and II reactivity were substantially reduced in all patients, and C1q binding to anti-HLA was abolished. IdeS also cleaved the IgG-type B cell receptor on CD19+ memory B cells. Anti-IdeS antibodies developed 1 week after treatment, peaking at 2 weeks. A few hours after the second IdeS infusion, 1 patient received a deceased donor kidney offer. At enrollment, the patient had a positive serum crossmatch (HLA-B7), detected by complement-dependent cytotoxicity, flow cytometry, and multiplex bead assays. After IdeS infusion (0.12 mg/kg ×2) and when the HLA-incompatible donor (HLA-B7+) kidney was offered, the HLA antibody profile was negative. The kidney was transplanted successfully.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
653 a Clinical research/practice
653 a Clinical trial
653 a Crossmatch
653 a Desensitization
653 a Histocompatibility
653 a Kidney transplantation/nephrology
653 a Kidney transplantation: living donor
653 a Pharmacokinetics/pharmacodynamics
653 a clinical research/practice
7001 a Bengtsson, Matsu Uppsala universitet,Uppsala University,Klinisk immunologi4 aut0 (Swepub:uu)matsbs
7001 a Eich, Torsten,d 1972-u Uppsala universitet,Uppsala University,Klinisk immunologi4 aut0 (Swepub:uu)toeic517
7001 a Eriksson, Britt-Marie,c Docent,d 1952-u Uppsala universitet,Uppsala University,Infektionssjukdomar4 aut0 (Swepub:uu)breri424
7001 a Winstedt, Lenau Hansa Medical AB, Lund, Sweden4 aut
7001 a Järnum, Sofiau Hansa Medical AB, Lund, Sweden4 aut0 (Swepub:lu)nkir-sja
7001 a Stenberg, Yvonneu Hansa Medical AB, Lund, Sweden4 aut
7001 a Robertson, Anna Karinu Hansa Medical AB, Lund, Sweden4 aut
7001 a Mosén, Kristinau Hansa Medical AB, Lund, Sweden4 aut
7001 a Björck, Larsu Lund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Clinical Sciences, Division of Infection Medicine, Lund University, Lund, Sweden4 aut0 (Swepub:lu)medk-lbj
7001 a Bäckman, Larsu Uppsala universitet,Uppsala University,Transplantationskirurgi4 aut0 (Swepub:uu)larba545
7001 a Larsson, Eriku Uppsala universitet,Uppsala University,Klinisk och experimentell patologi4 aut0 (Swepub:uu)eriklars
7001 a Wood, Kathrynu Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK4 aut
7001 a Tufveson, Gunnaru Uppsala universitet,Uppsala University,Transplantationskirurgi4 aut0 (Swepub:uu)gutuf839
7001 a Kjellman, Christianu Hansa Medical AB, Lund, Sweden4 aut0 (Swepub:lu)wbl-ckj
7102 a Uppsala Universityb Transplantationskirurgi4 org
7730 t American Journal of Transplantationd : Elsevier BVg 18:11, s. 2752-2762q 18:11<2752-2762x 1600-6135x 1600-6143
8564 u http://dx.doi.org/10.1111/ajt.14733x freey FULLTEXT
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.14733
8564 u https://doi.org/10.1111/ajt.14733y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1265861/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://lup.lub.lu.se/record/2ae4db3b-b59d-4e03-becb-43214eb0229d
8564 8u https://doi.org/10.1111/ajt.14733
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-366863

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy